Studiensammlung

Zurück zur Übersicht

Filter zurücksetzen

Studiensammlung zu HIV

Protopapas, K. et al: Public Awareness towards the U=U Statement A Multi-Country Survey (Austria, Greece and Switzerland)

22.-26.07.2024 / IAS

Miralles, C. et al: Switching to B/F/TAF in a Real-World Cohort of Older People with HIV and a High Burden of Non-AIDS related comorbities

22.-26.07.2024 / IAS

Avihingsanon, A. et al: Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With HIV-1 and HBV

03.-06.03.2024 / CROI

Sabranski, M. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort.

18.-21.10.2023 / EACS 2023

Esser, S. et al: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study.

18.-21.10.2023 / EACS 2023

Stephan, C. et al: Longer-Term (3-Year) Effectiveness and Safety of B/F/TAF for the Treatment of HIV in the German BICSTaR Cohort

23.-25.03.2023 / DÖAK

Schellberg, S. et al: Three-Year B/F/TAF Use in Treatment-Naive and Treatment-Experienced People Living With HIV in the BICSTaR Cohort Study

23.-25.03.2023 / DÖAK

Ogbuagu, O. et al: Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH

19.-23.02.2023 / CROI

Avihingsanon, A. et al: Predictors of Hepatitis B treatment response in people with HIV-1/HBV coinfection

19.-22.02.2023 / CROI

Trottier, B. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study

23.-26.10.2022 / HIV Drug Therapy 2022

Castagna. A. et al: Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study)

23.-26.10.2022 / HIV Drug Therapy 2022

Chastek, B. et al: ART Regimen Persistence Among Treatment-Experienced Patients With HIV Switching to a MTR or STR Since 2018

23.-26.10.2022 / HIV Drug Therapy 2022

Orkin, C. et al: Outcomes After Switching From 144 Weeks of Blinded DTG/ABC/3TC or DTG+F/TAF to 96 Weeks of Open-label B/F/TAF

23.-26.10.2022 / HIV Drug Therapy 2022

Ramgopal, M. et al: 5-Year Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials

23.-26.10.2022 / ID Week 2022

Ogbuagu, O. et al: Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People With Multi-Drug Resistant HIV: Week 52 Results

19.-23.10.2022 / ID Week 2022

Margot N. et al.: Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People With HIV After 52 Weeks of Treatment

29.07.-02.08.2022 / AIDS 2022

Rodriguez C. A. et al.: One Year Outcome of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Children ≥ 2 Years Weighing 14 to < 25 kg

29.07.-12.08.2022 / AIDS 2022

Wohl D. A. et al.: B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults

12.-16.02.2022 / CROI

Ogbuagu O. et al.: Long-Acting Lenacapavir in People With Multidrug-Resistant HIV-1: Week 52 Results

12.-16.02.2022 / CROI

Andreatta K. et al.: Prevalence and Risk Factors of Preexisting TAMs in Clinical Trial Participants and Sustained Viral Suppression After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

27.-30.10.2021 / EACS

Brunetta J. et al.: Patient-reported outcome (PRO) measures at 12 mo. in a real-world cohort of people living with HIV with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada and Israel

27.-30.10.2021 / EACS

Mallolas J. et al.: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 12-month effectiveness, persistence, and safety in a multi-country cohort study

27.-30.10.2021 / EACS

Margot, N. et al: Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People with HIV after 26 Weeks of Treatment

27.-30.10.2021 / EACS

Andreatta, K. et al: Long-term Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide After Switch From Boosted Protease Inhibitor-Based Regimens Including in Those With Preexisting Resistance and Viral Blips

27.-30.10.2021 / EACS

Andreatta, K. et al: High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in African-American Adults With HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence

29.09.-03.10.2021 / ID Week

Daar, E. et al: Incidence of Metabolic Complications Among Treatment-naïve Adults Living With HIV-1 Randomized to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF After 3 Years

29.09.-03.10.2021 / ID Week

Acosta, R. et al: Unreturned Pill Bottles in the 1489 and 1490 Clinical Trials: An Important Measure of Poor Adherence That Is Often Ignored in Pill Count Calculations

29.09.-03.10.2021 / ID Week

Molina, J.M. et al: Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People with HIV: Week 26 results (CAPELLA study)

18.-21.07.2021 / IAS

Maggiolo, F. et al: Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: Week 96 results from an international, phase 3b, open-label trial (GS-US-380-4449)

18.-21.07.2021 / IAS

Kumar P. et al.: Week 72 Outcomes and COVID-19 Impact From the BRAAVE 2020 Study: a Randomized Switch to B/F/TAF in Black American Adults With HIV

18.-21.07.2021 / IAS

Arribas, J. et al: Long-term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-up

18.-21.07.2021 / IAS

Andreatta, K. et al: Long-term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide From Dolutegravir/Abacavir/Lamivudine With Preexisting Resistance and Viral Blips

18.-21.07.2021 / IAS

Acosta R. K. et al.: Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naïve Clinical Trials

18.-21.07.2021 / IAS

Natukunda E. et al: B/F/TAF In Virologically Suppressed Adolescents and Children: Two-year Outcomes in 6 to <18 Year Olds and Six-month Outcomes in Toddlers

16.-17.06.2021 / International Workshop on HIV & Pediatrics

Segal-Maurer, S. et al: Potent Antiviral Activity of Lenacapavir in Phase 2/3 in Heavily ART-Experienced PWH

06.-10.03.2021 / CROI 2021

Workowski, K. et al: Four-Year Outcomes of B/F/TAF in Treatment-Naïve Adults

06.-10.03.2021 / CROI